FDA places partial clinical hold on Bright Minds' BMB-101 epilepsy trial over mouse toxicity
The hold on the Phase 2 seizure study clouds the biotech's lead program after animal toxicity findings.
Read at Yahoo Finance →Full coverage · 10 outlets
- Yahoo Finance · lead
- Fierce BiotechFDA dims Bright Minds’ outlook with partial hold on seizure trial over toxicity in mice
- Stock TitanThe FDA put Bright Minds' planned seizure study partly on hold, citing toxicity findings in mice.
- DealroomFDA places partial clinical hold on Bright Minds' BMB-101 Phase 2 epilepsy trial
- The Clinical Trial VanguardBright Minds’ BMB-101 Hold Exposes a Recurring Failure in Preclinical-to-IND Translation
- Seeking AlphaBright Minds Biosciences: Downgrade To 'Hold' On BMB-101 Setback DEE And Progression Into PWS
- herald-dispatch.comBright Minds Biosciences Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into Bright Minds Biosciences (DRUG)
- The Manila TimesBright Minds Biosciences Provides Update About Planned Study with BMB-101 in Developmental and Epileptic Encephalopathies
- MarketBeatDRUG News Today | Why did Bright Minds Biosciences stock drop today? $DRUG
- MSNFDA puts partial hold on Bright Minds’ Phase II seizure study